Literature DB >> 6709484

Adverse effects of drugs on the blood.

J S Meulenhoff.   

Abstract

Amongst adverse drug reactions blood dyscrasias are not frequent, but they may have serious consequences. Compared with Sweden, data from The Netherlands are scarce. It is to be expected that regular reports about the incidence of drug-induced blood dyscrasias may play an important role in general prevention. Blood dyscrasias may be caused by a variety of drugs, from many pharmacotherapeutic groups with diverse chemical structures and with all application forms. Metabolism and distribution may influence the activity of drugs. Drug-induced anaemias, including aplastic anaemia, are briefly discussed. Toxic and immune mechanisms may occur. The same holds with regard to the leucopenias. Drug-induced thrombocytopenia is mainly immune-mediated (cytostatics being excluded as causative agents). In immune-mediated drug-induced blood dyscrasias often haptens must be formed. They can be formed in vivo in the liver or in the lymphocytes. In some cases they appear to be formed even in vitro. Tracing the causative agent of a dyscrasia, be it a drug or some other substance, requires a series of investigations, comprising usage of the drug, serology and cell culture. Provocation tests are seldom justified. Distinct preventive measures can be taken to minimize the risk of blood dyscrasias: avoidance of risky drugs, awareness of the patient about early clinical signs and haematological control.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6709484     DOI: 10.1007/bf01960198

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  25 in total

1.  Immune thrombocytopenia due to a metabolite of para-aminosalicylic acid.

Authors:  E V Eisner; K Kasper
Journal:  Am J Med       Date:  1972-12       Impact factor: 4.965

2.  Deficient sulphoxidation status and D-penicillamine toxicity.

Authors:  G S Panayi; G Huston; R R Shah; S C Mitchell; J R Idle; R L Smith; R H Waring
Journal:  Lancet       Date:  1983-02-19       Impact factor: 79.321

3.  Effect of storage of penicillin-G solutions on sensitisation to penicillin-G after intravenous administration.

Authors:  K A Neftel; M Wälti; H Spengler; A L de Weck
Journal:  Lancet       Date:  1982-05-01       Impact factor: 79.321

4.  Systemic lupus erythematosus: causative factors and treatment.

Authors:  K D Morley; G R Hughes
Journal:  Drugs       Date:  1982-06       Impact factor: 9.546

Review 5.  Allergic reactions in man.

Authors:  C W Parker
Journal:  Pharmacol Rev       Date:  1982-03       Impact factor: 25.468

6.  Feprazone: absence of hemolytic effects in glucose-6-phosphate dehydrogenase-deficient subjects.

Authors:  T Meloni; G Forteleoni; M Serra; S Daniotti; L Negri; P Giuntini; L Canepa; G F Gaetani
Journal:  J Clin Pharmacol       Date:  1982 Aug-Sep       Impact factor: 3.126

Review 7.  Drug-induced agranulocytosis.

Authors:  V Pisciotta
Journal:  Drugs       Date:  1978-02       Impact factor: 9.546

8.  Neutropenia after penicillins: toxic or immune-mediated?

Authors:  K A Neftel; M Wälti; H Spengler; A von Felten; S A Weitzman; H Bürgi; A L de Weck
Journal:  Klin Wochenschr       Date:  1981-08-17

9.  Penicillin-G degradation products inhibit in vitro granulopoiesis.

Authors:  K A Neftel; M R Müller; M Wälti; J Erni; M Gugler; S Arrenbrecht
Journal:  Br J Haematol       Date:  1983-06       Impact factor: 6.998

10.  Hemolytic anemia and sulfhemoglobinemia due to phenacetin abuse: a case with multivisceral adverse effects.

Authors:  P Basset; J P Bergerat; J M Lang; F Oberling; B Gillet
Journal:  Clin Toxicol       Date:  1981-04       Impact factor: 4.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.